ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Amlodipine

Also written as “amlodipine”, “Amlodipine 5 mg” and “Amlodipine 10 mg”.

Its studies are mostly in Hypertension · Essential Hypertension · Hyperlipidemias · Kidney Diseases · Hypercholesterolemia, led by 35 companies.

Drug pageAmlodipine: every studyMany companies study it; this page follows only the 170 they lead. All 284 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 25, 2005170 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only570 open or runningphase 4since Aug 25, 2005Aug 25, 2005none ahead
Boehringer Ingelheimits history only220 open or runningphase 4since Oct 14, 2005Oct 14, 2005none ahead
Viatrisits history only130 open or runningphase 4since Aug 31, 2005Aug 31, 2005none ahead
Hanmi Pharmaceuticalits history only110 open or runningphase 3since Jul 14, 2009Jul 14, 2009none ahead
Dr. Reddy's Laboratoriesits history only80 open or runningphase 1since May 26, 2010May 26, 2010none ahead
HK inno.Nits history only50 open or runningphase 3since Feb 16, 2015Feb 10, 2014none ahead
Handokits history only40 open or runningphase 3since Jul 24, 2022Jul 21, 2020none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 9, 2009Feb 9, 2009none ahead
Yuhanits history only41 open or runningphase 4since Sep 4, 2023May 29, 2014none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Jan 8, 2016Feb 14, 2014none ahead
Organon10 open or runningphase 4since Aug 30, 2005Aug 30, 2005none ahead

Also a collaborator on its studies: CSPC Pharmaceutical Group and Integrium.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Organon only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 30, 2005First study: phase 4 study in Kidney DiseasesFirst studyNCT00140985 · 97 enrolled

TargetBeta

“Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149
GabapentinruleViatrisphase 449
DronedaroneruleSanofiphase 418
NifedipineruleBayerphase 418

Studies

The one study Organon leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00140985Kidney Diseases4CompletedJan 200297

How it is read

Names in the registry

  • “Amlodipine”, 44 entries
  • “amlodipine”, 14 entries
  • “Amlodipine 5 mg”, 9 entries
  • “Amlodipine 10 mg”, 6 entries
  • “valsartan + amlodipine”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.